In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: A 24-country study

Richard V. Goering, C. E. Nora, R. Hare, F. Sabatelli, K. Aldridge, P. Della-Latta, J. Dick, M. J. Ferraro, J. Hindler, D. Bruckner, M. Jacobs, R. Jones, D. Low, A. Medeiros, J. Boyce, B. Murray, F. Baquero, D. Costa, N. Frimodt-Moller, H. GoossensD. Graninger, S. Gudmundsson, D. Gur, P. Huovinen, M. Kettner, E. Keuleyan, K. Klugman, R. Le Clercq, J. Patzer, G. Petrikkos, E. Lingas, C. E. Nord, G. Reshedko, L. Stratchounski, J. Schindler, G. C. Schito, J. Verhoef, B. Wiedermann, R. Wise

Research output: Contribution to journalArticle

2 Scopus citations


Objective. To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents. Methods. Pecent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated. Results. Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions. Conclusions. Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.

Original languageEnglish
Pages (from-to)549-556
Number of pages8
JournalClinical Microbiology and Infection
Issue number10
Publication statusPublished - Oct 2000


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Microbiology

Cite this